<DOC>
	<DOC>NCT01959165</DOC>
	<brief_summary>This is a multi-centre, randomised, double-blind, placebo controlled, parallel group, Phase II study to evaluate efficacy and safety of 3 doses of MEDI7183, in Japanese subjects with moderate to severe UC</brief_summary>
	<brief_title>MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Diagnosis of UC established by clinical and endoscopic evidence and corroborated by a histopathology report Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with rectosigmoidoscopy score ≥ 2 during screening period Demonstrated an inadequate response to, loss of response to, or intolerance to at least one of immunomodulators or Anti TNFα agents. etc. Disease limited to the rectum Toxic megacolon Crohn's Disease History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC Planned bowel surgery within 12 weeks from Visit 2 Stool positive for C. difficile toxin at screening Primary Sclerosing Cholangitis History of gastrointestinal surgery within 8 weeks of Visit 2 Any uncontrolled or clinically significant systemic disease Condition or disease that, in the opinion of the investigator would pose a risk to subject safety or interfere with study evaluation, procedures or completion Subjects with positive HBsAg, HBsAb, HBcAb or HCVAb serology at screening etc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ulcerative Colitis, Japanese, subcutaneously</keyword>
</DOC>